Eddy Saad, MD, MSc

Articles

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26th 2024

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

Eddy Saad, MD, MSc

August 8th 2024

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Published: August 22nd 2024 | Updated: August 29th 2024

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors

Published: August 6th 2024 | Updated: August 19th 2024

Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

Published: July 9th 2024 | Updated: July 10th 2024

Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors

Published: June 2nd 2024 | Updated: June 3rd 2024

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

Published: September 12th 2024 | Updated: September 17th 2024

State of the Science Summit - Breast Cancer: Chaired by Jairam Krishnamurthy, MD, FACP

Published: September 15th 2024 | Updated: September 17th 2024

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in Early TNBC

Latest Conference Coverage

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Eddy Saad, MD, MSc

Articles

Latest Updated Articles

Latest Conference Coverage